(ANVS) Annovis Bio - Overview
Stock: Buntanetap, ANVS405, ANVS301
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 92.0% |
| Relative Tail Risk | -17.8% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.30 |
| Alpha | -39.58 |
| Character TTM | |
|---|---|
| Beta | 1.395 |
| Beta Downside | 1.541 |
| Drawdowns 3y | |
|---|---|
| Max DD | 94.48% |
| CAGR/Max DD | -0.53 |
Description: ANVS Annovis Bio December 22, 2025
Annovis Bio, Inc. (NYSE: ANVS) is a U.S.-based clinical-stage biotech that focuses on small-molecule therapies for neurodegenerative disorders. Its lead candidate, Buntanetap, is advancing in a Phase 2/3 trial for Alzheimer’s disease, a Phase 3 trial for Parkinson’s disease, and a Phase 2 study for Lewy body dementia. The pipeline also includes ANVS-405, currently in Phase 2/3 for traumatic brain injury and stroke, and ANVS-301, which has completed Phase 1 for later-stage Alzheimer’s disease and dementia. The company was founded in 2008 and is headquartered in Malvern, Pennsylvania.
Key market and financial context (as of Q3 2024): the global Alzheimer’s therapeutics market is projected to exceed $6 billion by 2028, growing at a 7-8% CAGR, providing a sizable addressable market for Buntanetap. Annovis reported a cash runway of roughly 12 months and a market capitalization near $150 million, indicating limited liquidity that could pressure upcoming financing needs. The biotech sector’s R&D spend has risen ~8% YoY, reflecting strong investor appetite for novel neuro-degeneration platforms, but also intensifying competition for talent and capital.
For a deeper, data-driven look at how Annovis stacks up against peers, you might find it useful to explore ValueRay’s analytical tools.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -1.45 > 0.02 and ΔFCF/TA 14.66 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -1.45 > 3% & CFO -25.0m > Net Income -24.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (19.7m) vs 12m ago 51.70% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -1139 > 6 (EBITDA TTM -26.6m / Interest Expense TTM 16.9k) |
Altman Z'' -15.00
| A: 0.78 (Total Current Assets 17.2m - Total Current Liabilities 3.73m) / Total Assets 17.2m |
| B: -8.95 (Retained Earnings -153.9m / Total Assets 17.2m) |
| C: -1.22 (EBIT TTM -19.3m / Avg Total Assets 15.8m) |
| D: -38.15 (Book Value of Equity -153.9m / Total Liabilities 4.03m) |
| Altman-Z'' Score: -72.33 = D |
What is the price of ANVS shares?
Over the past week, the price has changed by -7.78%, over one month by -32.15%, over three months by +25.13% and over the past year by -9.12%.
Is ANVS a buy, sell or hold?
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ANVS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 13.8 | 452.2% |
| Analysts Target Price | 13.8 | 452.2% |
| ValueRay Target Price | 1.6 | -37.3% |
ANVS Fundamental Data Overview February 03, 2026
Revenue TTM = 0.0 USD
EBIT TTM = -19.3m USD
EBITDA TTM = -26.6m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = -15.3m USD (from netDebt column, last quarter)
Enterprise Value = 44.5m USD (59.8m + (null Debt) - CCE 15.3m)
Interest Coverage Ratio = -1139 (Ebit TTM -19.3m / Interest Expense TTM 16.9k)
EV/FCF = -1.78x (Enterprise Value 44.5m / FCF TTM -25.0m)
FCF Yield = -56.11% (FCF TTM -25.0m / Enterprise Value 44.5m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.59 (Enterprise Value 44.5m / Total Assets 17.2m)
Interest Expense / Debt = unknown (Interest Expense 16.9k / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = -15.2m (EBIT -19.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.60 (Total Current Assets 17.2m / Total Current Liabilities 3.73m)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = 0.58 (negative EBITDA) (Net Debt -15.3m / EBITDA -26.6m)
Debt / FCF = 0.61 (negative FCF - burning cash) (Net Debt -15.3m / FCF TTM -25.0m)
Total Stockholder Equity = 16.2m (last 4 quarters mean from totalStockholderEquity)
RoA = -157.7% (out of range, set to none)
RoE = -153.5% (Net Income TTM -24.9m / Total Stockholder Equity 16.2m)
RoCE = -143.4% (out of range, set to none) (EBIT -19.3m / Capital Employed (Total Assets 17.2m - Current Liab 3.73m))
RoIC = -93.99% (negative operating profit) (NOPAT -15.2m / Invested Capital 16.2m)
WACC = 11.05% (E(59.8m)/V(59.8m) * Re(11.05%) + (debt-free company))
Discount Rate = 11.05% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 43.76%
Fair Price DCF = unknown (Cash Flow -25.0m)
EPS Correlation: 63.56 | EPS CAGR: 10.40% | SUE: 0.69 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.37 | Chg30d=+0.170 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-1.34 | Chg30d=-0.520 | Revisions Net=-1 | Growth EPS=+6.3% | Growth Revenue=+0.0%